J 2022

Insights into Antimalarial Activity of N-Phenyl-Substituted Cinnamanilides

KOS, Jiří; Gilles DEGOTTE; Dominika PINDJAKOVA; Tomáš STRHÁRSKY; Timotej JANKECH et al.

Basic information

Original name

Insights into Antimalarial Activity of N-Phenyl-Substituted Cinnamanilides

Authors

KOS, Jiří; Gilles DEGOTTE; Dominika PINDJAKOVA; Tomáš STRHÁRSKY; Timotej JANKECH; Tomáš GONĚC; Pierre FRANCOTTE; Michel FREDERICH and Josef JAMPILEK

Edition

Molecules, Basel, MDPI, 2022, 1420-3049

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Switzerland

Confidentiality degree

is not subject to a state or trade secret

References:

Impact factor

Impact factor: 4.600

Marked to be transferred to RIV

Yes

RIV identification code

RIV/00216224:14110/22:00127693

Organization unit

Faculty of Medicine

EID Scopus

Keywords in English

cinnamanilides; antiplasmodial activity; Plasmodium; structure-activity relationships

Tags

International impact, Reviewed
Changed: 27/1/2023 10:52, Mgr. Tereza Miškechová

Abstract

In the original language

Due to the urgent need of innovation in the antimalarial therapeutic arsenal, a series of thirty-seven ring-substituted N-arylcinnamanilides prepared by microwave-assisted synthesis were subjected to primary screening against the chloroquine-sensitive strain of P. falciparum 3D7/MRA-102. The lipophilicity of all compounds was experimentally determined as the logarithm of the capacity factor k, and these data were subsequently used in the discussion of structure-activity relationships. Among the screened compounds, fourteen derivatives exhibited IC50 from 0.58 to 31 µM, whereas (2E)-N-(4-bromo-2-chlorophenyl)-3-phenylprop-2-enamide (24) was the most effective agent (IC50 = 0.58 µM). In addition, (2E)-N-[2,6-dibromo-4-(trifluoromethyl)- phenyl]-3-phenylprop-2-enamide (36), (2E)-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-phenylprop- 2-enamide (18), (2E)-N-(2-bromo-5-fluorophenyl)-3-phenylprop-2-enamide (23), and (2E)-3-phenyl-N-(3,4,5-trichlorophenyl)prop-2-enamide (33) demonstrated efficacy in the IC50 range from 2.0 to 4.3 µM, comparable to the clinically used standard chloroquine. The results of a cell viability screening performed using THP1-Blue™ NF-κB cells showed that none of these highly active compounds displayed any significant cytotoxic effect up to 20 μM, which makes them promising Plasmodium selective substances for further investigations.